Individualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE
November 13, 2015•14 min
Host: Jennifer Caudle, DO
Guest: Alok A. Khorana, M.D.
Join Prof. Alok Khorana as he is interviewed on the the place for direct oral anticoagulants in the individualization of VTE treatment and prevention of recurrence. This session will highlight the unique experience and therapeutic knowledge of Prof. Khorana, broadening listeners’ perspectives and enlightening new methods of treating, diagnosing and thinking about current medical issues related to VTE facing clinicians. Since the recording of this program, the 'Antithrombotic Therapy for VTE Disease: CHEST Guideline' (Kearon C, et al. CHEST 2016, doi: 10.1016/j.chest.2015.11.026) has been published online. Recommendations from the new guidelines have been incorporated into the visual presentation but are not reflected in the audio portion, and include the following: For VTE and no cancer, as long-term anticoagulant therapy, we suggest dabigatran (Grade 2B), rivaroxaban (Grade 2B), apixaban (Grade 2B) or edoxaban